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The technology allowing freezing of RBC units has been available 
for many decades. The high-glycerol method for RBC storage at 
–80°C is predominantly used. Several studies have shown satis-
factory results regarding the in vitro viability and function of cryo-
preserved RBCs. RBC freezing is nowadays mostly encountered in 
rare blood programs and military deployments. Preservation time 
of frozen RBCs appears to be virtually indefinite, but most coun-
tries apply a 10-year outdate. There is no mandatory time restric-
tion in France. The National Rare Blood Bank currently includes 
962 (17.5%) RBC units aged 10 years or more and 153 (2.8%) aged 
20 years or more. Since 1994, 1957 RBC units have been thawed 
and transfused, among which 118 were aged 10 years or more 
and 8 were aged 20 years or more. Discarding RBC units older 
than 10 years may be highly sensitive for very rare blood groups, 
e.g., U–, of which approximately 30 percent of the cryopreserved 
units are aged 10 years or more. However, the lack of nucleic acid 
testing for HIV and HCV may be problematic for old RBC units 
drawn from donors who were not subsequently tested for these 
markers, which is now mandatory in most countries. Regarding 
the 118 transfused RBC units older than 10 years, no evidence of 
hemolysis of thawed RBCs and no transfusion reaction, clinical 
or biologic hemolysis, or transfusion ineffectiveness was reported, 
either by any of the parties involved in the transfusion supply of 
rare RBC units or through the French hemovigilance program, 
which requires a mandatory report of any transfusion reaction. 
It has recently been suggested to extend the 10-year restriction 
in some countries. Considering our experience and observational 
data, we may consider it safe and efficient to transfuse rare fro-
zen RBC units older than 10 years. An international consensus 
for RBC cryopreservation time should ideally be established. 
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Humans have experimented with blood transfusions for more than 300 years and attempted to preserve human blood since the early 1900s. The first mod-
ern approach to blood storage, with a citrate-glucose solu-
tion, was stimulated by World War I. Long-term storage 
of RBCs using glycerol as a cryopreservative was initially 
implemented in the early 1950s.1,2 Two methods have been 
described: the low-glycerol method, for freezing units in 
liquid nitrogen at –196°C, and the high-glycerol method for 
storage of RBCs at –80°C. The technology that is currently 
predominantly used is the high-glycerol technique, which 
was initially developed in the 1960s and early 1970s by the 
American Red Cross Research Laboratory (Washington, 
DC) and the U.S. Naval Blood Research Laboratory (Bos-
ton, MA).
The technology allowing freezing of RBC units has been 
available for more than four decades. In addition to long-
term storage, RBC cryopreservation has other advantages, 
which are mainly related to the necessary washing proce-
dure for glycerol removal once units are thawed. Indeed, 
washing of thawed RBCs eliminates most cell debris, WBCs, 
platelets, cytokines, residual plasma, and free hemoglobin. 
However, RBC cryopreservation has never reached the ex-
pected popularity; it is still infrequently used, especially 
because of the labor-intensiveness and expense of the pro-
cedure, as well as the RBC loss through the process and lim-
ited shelf life of thawed RBC units. As a result, stockpiling of 
frozen inventory RBCs is today mostly encountered in rare 
blood program management and military deployments.
Organization of the Rare Blood Program in France
French regulations stipulate that a blood group is re-
garded as rare if its prevalence is 4 in 1000 or less (i.e., ≤1 
in 250) in the general population.3 A national rare blood 
donor database was implemented in our country in the late 
1960s to ensure the transfusion and obstetric safety of pa-
tients with rare blood phenotypes.4 A national rare blood 
bank was set up in the early 1980s.5 Potential rare blood 
donors from the national database are highly encouraged to 
donate blood on a routine basis for the National Rare Blood 
Bank. This facility is located in Créteil (a few kilometers 
from Paris) and is comanaged by the National Institute of 
Blood Transfusion (INTS, Paris) and the French Blood Es-
tablishment (EFS Ile de France, Paris). The confirmation of 
the rare blood type, registration of new people with a rare 
blood group in the national database, and selection and de-
livery agreement of rare blood units are exclusively carried 
out by the National Reference Laboratory for Blood Groups 
(CNRGS, Paris), a department of the INTS, Paris. To date, 
9508 individuals (patients and donors) are enlisted in the 
national registry of people with rare blood phenotypes or 
genotypes.
Rare blood units from the National Rare Blood Bank are 
frozen according to the Cohn method, using glycerol in an 
ionic medium to achieve a final glycerol concentration of 40 
percent (wt/vol), the so-called high-glycerol method. RBCs 
are subsequently stored at a mean temperature of –80°C 
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(range –65° to –90°C). Since late 2005, the Haemonetics 
Automated Cell Processor (ACP) 215 closed-circuit instru-
ment (Haemonetics Corp., Braintree, MA) has been sys-
tematically used to glycerolize and deglycerolize human 
RBCs, allowing for a 7-day shelf life for thawed units when 
stored at 2° to 6°C in a saline-adenine-glucose-mannitol 
(SAGM) additive solution.6 Older RBC units are handled 
with the Cobe 2991 Cell Processor (COBE BCT, Lakewood, 
CO), with a 24-hour shelf life for thawed units resuspended 
in SAGM. According to the French current rules, the quality 
control of the thawed RBC units consists in the hemoglo-
bin measurement (≥35 g/unit), hematocrit determination 
(50% to 80% for RBC units handled in an open circuit, 40% 
to 70% for those handled in a closed circuit), extracellular 
hemoglobin measurement (≤1.2% of total hemoglobin), 
and extracellular glycerol measurement (≤1 g/unit). Both 
open-circuit and closed-circuit technologies have been vali-
dated. It was shown for the open-circuit and closed-circuit 
procedures that the postthawing mean extracellular hemo-
globin was 0.21 percent (0.06% to 0.57%) and 0.16 percent 
(0.11% to 0.25%), and the extracellular glycerol was 0.14 g 
(0.02 to 0.73 g) and 0.15 g (0.11 to 0.19 g), respectively.6 
Random sampling is used for the routine quality control of 
the thawed units according to the NF-ISO-2889 standard.
The National Rare Blood Bank currently includes 5503 
cryopreserved blood units, from 1630 blood donors. From 
2001 to 2005, an annual average of 161 rare blood units 
were transfused (i.e., 2.53 per 106 inhabitants per year) for 
an annual average of 28 patients and 70 transfusion epi-
sodes;7 149 rare blood units were transfused in 2006 and 
236 in 2007.
The Preservation Time of Rare Blood Units
Rare blood, by its very nature, is considered a rare re-
source, and its long-term storage is necessary. The pres-
ervation time of frozen RBC units appears to be virtually 
indefinite. However, the question of a maximum period of 
validity has often been raised.8–16 In September 1987, the 
Food and Drug Administration in the United States ap-
proved the change from a 3- to a 10-year outdate period for 
glycerol-frozen RBCs stored at –80°C. Most other countries, 
e.g., China and South Africa, currently apply this 10-year
outdate.17,18 The European guidelines from the Guide to the
Preparation, Use and Quality Assurance of Blood Compo-
nents state that storage of frozen RBC units is possible for at
least 10 years, provided that an adequate temperature can
be guaranteed (–60° to –80°C for the high-glycerol cryo-
preservation procedure).19 The Technical Manual of the
AABB, 16th edition (2008), states that “frozen RBCs must
be stored at temperatures colder than –65°C and will expire
after 10 years. Rare frozen units may be used beyond the
expiration date, but only after medical review and approval
that are based on the patient’s needs and the availability of
other rare compatible units.”20
Several studies have been performed to investigate the 
in vitro recovery and quality of deglycerolized RBCs.9,11–14 
Valeri et al.11 reported that RBCs frozen with 40 percent to 
45 percent (wt/vol) glycerol could be stored at –80°C for 
up to 37 years, with mean in vitro freeze-thaw-wash recov-
ery values of 75 percent, without affecting the RBC 2,3 DPG 
level and with hemolysis after 24 hours of postwash storage 
at 4°C usually less than 1 percent. All units tested were ster-
ile. Moreover, frozen RBC units that were stored for as long 
as 21 years and subsequently thawed, washed, and stored 
at 4°C for 24 hours have been shown to demonstrate an in 
vivo 24-hour posttransfusion survival value greater than 75 
percent.11 In 2004, a similar study was performed to inves-
tigate the in vitro quality of RBCs frozen with 40 percent 
(wt/vol) glycerol at –80°C for 14 years, deglycerolized with 
the Haemonetics ACP 215 instrument, and stored at 4°C in 
AS-1 or AS-3 for up to 3 weeks.13 Acceptable results were 
achieved (mean in vitro recovery value of 80 ± 7%), simi-
lar to those previously described, although deglycerolized 
RBCs in AS-1 exhibited significantly higher hemolysis than 
those in AS-3 after storage at 4°C for 7 to 21 days. Another 
study in 2004 examined RBC units that had been cryopre-
served in 40 percent (wt/vol) glycerol and stored at –80°C 
for up to 22 years.14 Postthawed RBCs had acceptable mean 
freeze-thaw-wash recovery and normal oxygen transport 
function, RBC morphology, RBC indices, methemoglobin, 
and osmotic fragility. Interestingly, it was also shown that 
the in vitro viability and function of cryopreserved RBCs 
was not dependent on the length of frozen storage or post-
thaw storage at 4°C, but was influenced by the length of 
storage at 4°C before cryopreservation: The more quickly 
the RBC units are frozen, the better are the in vitro viability 
and function of the thawed RBCs.
Despite the conclusions from these different stud-
ies advocating the possibility of storing RBCs well over 10 
years, the 10-year outdate has remained since 1978 in the 
United States and is still largely applied in rare blood banks 
throughout the world.
Storage and Transfusion of Frozen RBCs Beyond 10 
Years: The French Experience
Age of frozen RBC units and thawed transfused RBC units: 
statistical data
Between 1994 and 2007, a mean of 628 rare blood units 
per year were frozen in the National Rare Blood Bank. After 
blood donation, RBC units are frozen as rapidly as possible, 
ideally within 7 days. However, freezing blood up to the 42-
day maximum period of validity is still possible for exceed-
ingly rare types.  Since 2004, 13.2 percent of RBC units have 
been frozen within 7 days of blood donation, 88.2 percent 
within 14 days, and 97.0 percent within 21 days.
Despite European recommendations, no official man-
datory time limit regarding the validity period of rare frozen 
RBC units exists in France. The National Rare Blood Bank 
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currently includes 962 (17.5%) RBC units aged 10 years or 
more and 153 (2.8%) aged 20 years or more (Fig. 1). The 
average age of rare frozen RBC units is 6.1 years (maximum 
33.5 years). Since 1994, 1957 rare RBC units have been 
thawed and transfused, among which 118 (6.0%) were aged 
10 years or more and 8 (0.4%) aged 20 years or more (Fig. 
1). The average age of rare transfused RBC units is 3.6 years 
(maximum 23.8 years).
Rare RBC units older than 10 years
 Discarding rare blood units older than 10 years may 
be, ethically speaking, highly sensitive, as there are usually 
no alternative resources for the specified patients. If we de-
cided to discard all rare blood units aged 10 years or more, 
this would represent the destruction of 17.5 percent of the 
current French rare frozen RBC stock, which could be very 
problematic for some rare blood phenotypes. For example, 
240 Vel– (VEL:-1) rare RBC units are now cryopreserved, 
among which 64 (26.7%) are aged 10 years or more. For 
the Kp(b–) rare specificity (KEL:-4), 75 (32.8%) are aged 10 
years or more. For the U– rare specificity (MNS:-3,-4,-5), 
which is quite frequently requested in France for patients 
of Afro-Caribbean ancestry suffering from sickle cell dis-
ease,3,7 113 (29.7%) are aged 10 years or more.
Long-term preservation of rare RBC units and nucleic acid 
testing in blood donors
 A specific problem for long-term preservation of rare 
RBC units concerns testing for mandatory markers for 
transfusion-transmitted diseases according to the current 
national regulations. In France, the current mandatory and 
systematic serologic markers are anti-HIV-1/anti-HIV-2, 
anti-HCV, AgHBs and anti-HBc for HBV, and anti-HTLV-
I/anti-HTLV-II. In addition, nucleic acid testing (NAT) for 
HIV and HCV has been required since July 2001. For either 
serologic markers or NAT, RBC units drawn before their re-
spective official implementation date are considered valid, 
provided that a blood donation or blood sample has been 
subsequently tested, according to a so-called retroactive 
process. In our country, however, no testing is performed 
for that purpose on frozen samples from a biologic resource 
center. Presently, 4562 (82.9%) of the RBC units stored 
within the National Rare Blood Bank have been tested for 
all legal mandatory markers, including NAT, either in real 
terms or retroactively. RBC units confirmed by a retro- 
active NAT testing are considered fully valid for transfusion 
according to the French regulations.21 Another issue is the 
941 (17.1%) rare RBC units for which the corresponding 
donors have never been subsequently tested for NAT. RBC 
units aged 10 years or more represent 54.9 percent of these 
941 blood donations. These RBC units may also be used for 
transfusion, provided there is no alternative solution.21 Our 
current policy, however, is to progressively discard such 
units that were drawn from donors who were never subse-
quently tested for HIV NAT and HCV NAT. Nevertheless, 
this attitude requires a very special care for RBC units with 
an exceedingly rare phenotype, e.g., Jk(a–b–) (JK:-1,-2), 
HrS– (RH:-18), HrB– (RH:-34), Hy– (DO:-4), or Jr(a–). 
There are no specific rules in France about an optimal in-
ventory for a given rare blood type. However, the following 
criteria are usually taken into account when a decision has 
to be made about the destruction of rare RBC units from 
a donor who was never tested for NAT: alive or deceased 
blood donor; prevalence of the rare blood phenotype within 
the general population; and number of available frozen RBC 
units from other donors with the same rare blood group, in-
cluding D, C, E, c, e, K, Fya/Fyb, Jka/Jkb, S/s antigen match. 
If we consider the example of the Jr(a–) rare blood group, 
nine Jr(a–) blood donors are known in France, and the cur-
rent stock of Jr(a–) rare blood units is 15, among which 6 
units (40%) are aged 10 years or more. HIV and HCV NAT 
have never been performed in five of these nine Jr(a–) do-
nors, which affects 9 (60%) of the 15 Jr(a–) blood units. As 
a result, it does not seem reasonable to discard 60 percent 
of the Jr(a–) RBC units from the national stock, consider-
ing the highly sensitive ethical aspect of such a decision.
Rare RBC transfused units older than 10 years and the French 
hemovigilance data
 Between 1994 and 2007, 118 RBC units older than 10 
years were transfused. For every transfusion episode that 
involved an RBC unit aged 10 years or more, the CNRGS 
medical staff questioned the National Rare Blood Bank to 
learn whether a macroscopic hemolysis of the RBC super-
natant was visible after the thawing-washing procedure. 
In addition, no extracellular hemoglobin measurement 
greater than 1.2 percent of the total hemoglobin (threshold 
corresponding to the current French guidelines) has been 
found to date for thawed RBC units, according to the qual-
ity control scheme of the National Rare Blood Bank. The 
CNRGS staff has also asked whether the posttransfusion 
Fig. 1. Age of frozen RBC units in the National Rare Blood Bank and age of 
transfused rare RBC units.
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hemoglobin rise in the recipient was compatible with the 
one expected and whether there was any reported clinical 
or biologic transfusion reaction. Regarding the transfusion 
of the 118 units that were older than 10 years, no evidence 
for hemolysis of thawed RBCs and no transfusion reaction, 
clinical or biologic hemolysis, or transfusion ineffectiveness 
was reported that could be related to long-term storage be-
yond 10 years. 
Transfusion of RBCs older than 10 years has always 
been legal in France. As a consequence, it did not appear 
necessary to perform a full prospective or retrospective 
study justifying the possible use of such RBCs. However, we 
may consider our observational data about the transfusion 
safety and efficiency of RBC units older than 10 years reli-
able for two main reasons. 
The first reason lies in the close communication among 
all parties involved in the transfusion supply of rare RBC 
units, probably much stronger and closer than that of a 
standard blood transfusion. Indeed, every single rare RBC 
unit, delivery of which is exclusively authorized by the 
CNRGS, is strictly time-followed. The patient is carefully 
and closely monitored, and the transfusion outcome is sub-
sequently discussed between the medical staff in charge of 
the patient and the CNRGS staff. 
The second reason is the presence of an active hemo- 
vigilance program in France since 1994, the rules of which 
are clearly defined according to the French regulations.22–24 
The report of every adverse transfusion reaction by anyone 
within the transfusion chain is strictly mandatory, whatever 
the intensity, seriousness, and imputability of the reaction. 
A transfusion reaction is defined in France as an “unex-
pected or undesired event, due or susceptible to be due to 
the transfusion of a blood product.”23 The precise list of the 
clinical or biologic manifestations that may occur during 
or after a blood transfusion and that must lead to a hemo- 
vigilance report is legally stipulated.23,24 Any unexpected or 
undesired clinical manifestation has to be reported. These 
include hemoglobinuria; positive direct antiglobulin test; 
rise in bilirubin; and failure of expected hemoglobin incre-
ment, estimated through the hemoglobin measurement 
performed within 24 hours after transfusion.
Between 1994 and 2007, no transfusion reaction was 
reported for any of the 118 rare RBC units older than 10 
years that were transfused. As a result, our observational 
data may provide new arguments for the safe and efficient 
use of very long-term cryopreserved RBC units.
Conclusions
Between 1994 and 2007, 118 rare blood units aged 10 
years or more (6.0%) and 8 (0.4%) aged 20 years or more 
were transfused in France. The maximum age of a rare RBC 
transfused unit was approximately 24 years. No transfusion 
reactions potentially linked to the long-term preservation of 
blood units older than 10 years were reported, either by the 
medical staff involved in the careful monitoring of the pa-
tients or through the French hemovigilance program, which 
requires a strict mandatory report of every transfusion adverse 
reaction, whatever its intensity or imputability. It has been 
quite recently suggested to extend the 10-year restriction 
for frozen RBC units in the United States.14 Based on our 
experience and observational data, we may consider it to be 
safe and efficient to transfuse rare frozen RBC units older 
than 10 years. Such a policy allows keeping a larger stock of 
frozen RBC units for the rarest phenotypes, to urgently meet 
the national or even international requests for rare blood. 
However, the question of a maximum time limit for rare 
frozen blood storage is still raised. Indefinite storage, theo-
retically possible, may be difficult because of ever-growing 
quality management requirements and constraints. The pe-
riod of validity of rare frozen RBC units should ideally be 
the same for all rare blood banks throughout the world. This 
point deserves consideration by the ISBT Working Party on 
Rare Donors  to establish an international consensus.
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